CA2910422C - Method of treating disease by auricular anesthesia of cranialnerves - Google Patents

Method of treating disease by auricular anesthesia of cranialnerves Download PDF

Info

Publication number
CA2910422C
CA2910422C CA2910422A CA2910422A CA2910422C CA 2910422 C CA2910422 C CA 2910422C CA 2910422 A CA2910422 A CA 2910422A CA 2910422 A CA2910422 A CA 2910422A CA 2910422 C CA2910422 C CA 2910422C
Authority
CA
Canada
Prior art keywords
pharmaceutical composition
subject
use according
administration
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2910422A
Other languages
English (en)
French (fr)
Other versions
CA2910422A1 (en
Inventor
Thomas M. Crews
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2910422A1 publication Critical patent/CA2910422A1/en
Application granted granted Critical
Publication of CA2910422C publication Critical patent/CA2910422C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
    • A61K31/245—Amino benzoic acid types, e.g. procaine, novocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4152—1,2-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. antipyrine, phenylbutazone, sulfinpyrazone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0046—Ear
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
CA2910422A 2013-05-03 2014-05-05 Method of treating disease by auricular anesthesia of cranialnerves Active CA2910422C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361819023P 2013-05-03 2013-05-03
US61/819,023 2013-05-03
PCT/US2014/036855 WO2014179814A1 (en) 2013-05-03 2014-05-05 Method of treating disease by auricular anesthesia of cranial nerves

Publications (2)

Publication Number Publication Date
CA2910422A1 CA2910422A1 (en) 2014-11-06
CA2910422C true CA2910422C (en) 2022-09-27

Family

ID=51844020

Family Applications (2)

Application Number Title Priority Date Filing Date
CA2910422A Active CA2910422C (en) 2013-05-03 2014-05-05 Method of treating disease by auricular anesthesia of cranialnerves
CA3004160A Active CA3004160C (en) 2013-05-03 2016-11-02 Method of treating disease by auricular anesthesia of cranial nerves

Family Applications After (1)

Application Number Title Priority Date Filing Date
CA3004160A Active CA3004160C (en) 2013-05-03 2016-11-02 Method of treating disease by auricular anesthesia of cranial nerves

Country Status (17)

Country Link
US (5) US20140357686A1 (enExample)
EP (2) EP2991620B1 (enExample)
JP (3) JP6433985B2 (enExample)
KR (2) KR102086709B1 (enExample)
CN (2) CN105163718B (enExample)
AU (2) AU2014262148B2 (enExample)
CA (2) CA2910422C (enExample)
DK (1) DK2991620T3 (enExample)
ES (1) ES2823624T3 (enExample)
HK (1) HK1212230A1 (enExample)
IL (2) IL242339B (enExample)
MX (2) MX381106B (enExample)
MY (2) MY180310A (enExample)
RU (2) RU2687249C2 (enExample)
SG (1) SG11201508509XA (enExample)
WO (2) WO2014179814A1 (enExample)
ZA (2) ZA201508782B (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2910422C (en) * 2013-05-03 2022-09-27 Thomas M. Crews Method of treating disease by auricular anesthesia of cranialnerves
EP3263103A4 (en) * 2015-02-26 2018-03-14 Limited Liability Company "konsortsium-pik" Pharmaceutical composition for treatment of inflammatory ear diseases, method for producing same and method for treatment using said composition
EP3509585B1 (en) 2016-09-07 2023-11-01 Glia, LLC Treatment of symptoms related to neurodegenerative disorders through pharmacological dermal activation of cranial nerves
US20220105052A1 (en) * 2016-12-26 2022-04-07 Cellix Bio Private Limited Compositions and methods for the treatment of chronic pain
CN107789621A (zh) * 2017-12-15 2018-03-13 阜阳市平衡医疗保健器械有限公司 一种治疗头痛的药物及其配制方法
US11607275B2 (en) * 2019-05-20 2023-03-21 Medtronic Ireland Manufacturing Unlimited Company Selection of hypertensive patients for treatment with renal denervation

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19524691A1 (de) * 1995-07-06 1997-01-09 Liedtke Pharmed Gmbh Methode und Zusammensetzung einer topischen Therapie von Innenohr und Labyrinth-Symptomen
RU2104056C1 (ru) * 1995-07-10 1998-02-10 Александр Александрович Ланцов Способ лечения периферических поражений лицевого нерва
JPH1094613A (ja) * 1996-08-02 1998-04-14 Mieko Sato 食欲調整用具
US6093417A (en) * 1999-01-11 2000-07-25 Advanced Medical Instruments Composition to treat ear disorders
AU5170400A (en) * 1999-05-27 2000-12-18 George F. El Khoury Topical application of muscarinic and opioid agents for treatment of tinnitus
DE10322497A1 (de) * 2003-05-19 2004-12-09 Liedtke, Rainer K., Dr. Topisch pharmakologische Vorbeugung und Therapie der Hyperakusis
US8940321B2 (en) * 2003-12-12 2015-01-27 Otic Pharma Ltd. Compositions for treatment of ear disorders and methods of use thereof
US8755892B2 (en) * 2007-05-16 2014-06-17 Cardiac Pacemakers, Inc. Systems for stimulating neural targets
WO2011019954A2 (en) * 2009-08-13 2011-02-17 Yehuda Ivri Intracochlear drug delivery to the central nervous system
WO2011028915A2 (en) * 2009-09-03 2011-03-10 University Of Chicago Platelet aggregation inhibitors
CA2848730A1 (en) * 2011-09-15 2013-03-21 Yoseph Yaacobi Systems and methods for treating ear disorders
CA2910422C (en) * 2013-05-03 2022-09-27 Thomas M. Crews Method of treating disease by auricular anesthesia of cranialnerves

Also Published As

Publication number Publication date
ES2823624T3 (es) 2021-05-07
JP7512317B2 (ja) 2024-07-08
AU2014262148B2 (en) 2018-11-22
JP2016522819A (ja) 2016-08-04
IL242339B (en) 2020-05-31
ZA201508782B (en) 2017-08-30
BR112018008893A8 (pt) 2019-02-26
MX2018005625A (es) 2018-12-06
AU2014262148A1 (en) 2015-11-05
RU2701548C1 (ru) 2019-09-30
WO2014179814A1 (en) 2014-11-06
MX2015015194A (es) 2016-02-11
BR112018008893A2 (pt) 2018-11-06
HK1212230A1 (en) 2016-06-10
EP3370716A4 (en) 2019-04-17
NZ713746A (en) 2021-01-29
JP6433985B2 (ja) 2018-12-05
JP2022065015A (ja) 2022-04-26
NZ742076A (en) 2024-12-20
AU2016349784B2 (en) 2019-06-06
CA3004160A1 (en) 2017-05-11
US20160051516A1 (en) 2016-02-25
ZA201803483B (en) 2019-08-28
US20220387307A1 (en) 2022-12-08
CA3004160C (en) 2023-03-14
MX381106B (es) 2025-03-04
RU2687249C2 (ru) 2019-05-08
EP2991620A4 (en) 2017-01-11
MX390998B (es) 2025-03-21
KR20160003012A (ko) 2016-01-08
EP3370716A1 (en) 2018-09-12
AU2016349784A1 (en) 2018-05-17
MY180310A (en) 2020-11-28
CN108430470A (zh) 2018-08-21
US20260083666A1 (en) 2026-03-26
US20140357686A1 (en) 2014-12-04
US20180360745A1 (en) 2018-12-20
JP2018536709A (ja) 2018-12-13
IL259019A (en) 2018-06-28
US11123284B2 (en) 2021-09-21
WO2017079270A1 (en) 2017-05-11
DK2991620T3 (da) 2020-10-12
KR20180088408A (ko) 2018-08-03
EP2991620A1 (en) 2016-03-09
MY196979A (en) 2023-05-16
CN105163718B (zh) 2020-03-17
CN105163718A (zh) 2015-12-16
IL259019B (en) 2021-06-30
KR102086709B1 (ko) 2020-03-09
KR102796310B1 (ko) 2025-04-16
RU2015148757A (ru) 2017-06-08
CA2910422A1 (en) 2014-11-06
US9968589B2 (en) 2018-05-15
EP2991620B1 (en) 2020-07-08
SG11201508509XA (en) 2015-11-27

Similar Documents

Publication Publication Date Title
US20260083666A1 (en) Method of treating disease
US9821164B2 (en) Electrical treatment of bronchial constriction
Loft et al. Hiccups: a case presentation and etiologic review
Jankovic Regional nerve blocks and infiltration therapy: Textbook and color atlas
NZ713746B2 (en) Method of treating disease by auricular anesthesia of cranial nerves
Repitsch et al. Functional electrical stimulation in facial rehabilitation
Angelova et al. Innovative approaches to the treatment of sleep apnoea
BR112018008893B1 (pt) Composição farmacêutica óptica
Chang Cervical Manipulation and Koren Specific Technique Emotions Protocol in the Improvement of Intensive Nocturnal Dry Cough: A Case Report
Dornhoffer et al. Pathophysiology of the Eustachian tube: The Patulous Eustachian tube

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20190503

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 11TH ANNIV.) - STANDARD

Year of fee payment: 11

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250425

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250425